172 related articles for article (PubMed ID: 8608054)
1. Economic and quality of life outcomes: the four-step pharmacoeconomic research model.
Arikian SR; Suver J; Einarson T; Doyle J
Oncology (Williston Park); 1995 Nov; 9(11 Suppl):33-6. PubMed ID: 8608054
[TBL] [Abstract][Full Text] [Related]
2. [Methodology of pharmacoeconomic studies in oncology].
Ballatori E
Recenti Prog Med; 2008 Jan; 99(1):42-7. PubMed ID: 18389873
[TBL] [Abstract][Full Text] [Related]
3. Pharmacoeconomics of cancer therapies: considerations with the introduction of biosimilars.
Henry D; Taylor C
Semin Oncol; 2014 Apr; 41 Suppl 3():S13-20. PubMed ID: 24767632
[TBL] [Abstract][Full Text] [Related]
4. Rank-order stability analysis (ROSA): testing pharmacoeconomic data.
Einarson TR; Arikian SR; Doyle JJ
Med Decis Making; 1995; 15(4):367-72. PubMed ID: 8544680
[TBL] [Abstract][Full Text] [Related]
5. The evaluation and use of economic evidence to inform cancer drug reimbursement decisions in Canada.
Yong JH; Beca J; Hoch JS
Pharmacoeconomics; 2013 Mar; 31(3):229-36. PubMed ID: 23322588
[TBL] [Abstract][Full Text] [Related]
6. A pharmacoeconomic modeling approach to estimate a value-based price for new oncology drugs in Europe.
Dranitsaris G; Ortega A; Lubbe MS; Truter I
J Oncol Pharm Pract; 2012 Mar; 18(1):57-67. PubMed ID: 21382915
[TBL] [Abstract][Full Text] [Related]
7. Economic impact of prescribing error prevention with computerized physician order entry of injectable antineoplastic drugs.
Nerich V; Borg C; Villanueva C; Thiery-Vuillemin A; Helias P; Rohrlich PS; Demarchi M; Pivot X; Limat S
J Oncol Pharm Pract; 2013 Mar; 19(1):8-17. PubMed ID: 22623276
[TBL] [Abstract][Full Text] [Related]
8. [Pharmacoeconomics and cost of cancer drugs].
Camps Herrero C; Caballero Díaz C; Blasco Cordellat A
Farm Hosp; 2010 Mar; 34 Suppl 1():12-5. PubMed ID: 20920852
[TBL] [Abstract][Full Text] [Related]
9. Pharmacoeconomic concepts in antiplatelet therapy: understanding cost-effectiveness analyses using clopidogrel as an example.
Weintraub WS
J Cardiovasc Pharmacol Ther; 2008 Jun; 13(2):107-19. PubMed ID: 18495905
[TBL] [Abstract][Full Text] [Related]
10. The use of decision analysis in the pharmacoeconomic evaluation of an antidepressant: a cost-effectiveness study of nefazodone.
Anton SF; Revicki DA
Psychopharmacol Bull; 1995; 31(2):249-58. PubMed ID: 7491376
[TBL] [Abstract][Full Text] [Related]
11. Pharmacoeconomic and clinical outcomes in oncology using oral chemotherapy.
Navarro RP; Morrow T; Baran R
Manag Care Interface; 2002 Jul; 15(7):55-62. PubMed ID: 12143298
[TBL] [Abstract][Full Text] [Related]
12. Are the true impacts of adverse events considered in economic models of antineoplastic drugs? A systematic review.
Pearce A; Haas M; Viney R
Appl Health Econ Health Policy; 2013 Dec; 11(6):619-37. PubMed ID: 24129649
[TBL] [Abstract][Full Text] [Related]
13. [Relevance of pharmacoeconomic analyses to price and reimbursement decisions in Austria].
Führlinger S
Wien Med Wochenschr; 2006 Dec; 156(23-24):612-8. PubMed ID: 17211765
[TBL] [Abstract][Full Text] [Related]
14. Guidelines for performing a pharmacoeconomic analysis.
Jolicoeur LM; Jones-Grizzle AJ; Boyer JG
Am J Hosp Pharm; 1992 Jul; 49(7):1741-7. PubMed ID: 1621734
[TBL] [Abstract][Full Text] [Related]
15. Pharmacoeconomic aspects in the treatment of curable and incurable cancer.
Jønsson V; Clausen SR; Hansen MM
Pharmacoeconomics; 1995 Oct; 8(4):275-81. PubMed ID: 10155669
[TBL] [Abstract][Full Text] [Related]
16. Overview of the arthritis Cost Consequence Evaluation System (ACCES): a pharmacoeconomic model for celecoxib.
Pettitt D; Goldstein JL; McGuire A; Schwartz JS; Burke T; Maniadakis N
Rheumatology (Oxford); 2000 Dec; 39 Suppl 2():33-42; discussion 57-9. PubMed ID: 11276801
[TBL] [Abstract][Full Text] [Related]
17. Multiple Dimensions of Value: Evaluative Frameworks for New Cancer Therapies.
Cheung MC; Sabharwal M; Chambers A; Han D; Sabarre KA; Chan K
J Clin Oncol; 2016 Apr; 34(12):1428-9. PubMed ID: 26884567
[No Abstract] [Full Text] [Related]
18. A pharmacoeconomic evaluation of cisplatin in combination with either etoposide or etoposide phosphate in small cell lung cancer.
Doyle JJ; Dezii CM; Sadana A
Semin Oncol; 1996 Dec; 23(6 Suppl 13):51-60. PubMed ID: 8996576
[TBL] [Abstract][Full Text] [Related]
19. Artificial neural network in pharmacoeconomics.
Polak S; Skowron A; Mendyk A; Brandys J
Stud Health Technol Inform; 2004; 105():241-9. PubMed ID: 15718613
[TBL] [Abstract][Full Text] [Related]
20. Economic outcomes and contemporary pharmacy practice.
Reeder CE
Am Pharm; 1993 Dec; NS33(12 Suppl):S3-6. PubMed ID: 8109541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
